GT Biopharma Q2 Loss Narrows, But Going Concern and Nasdaq Delisting Risks Persist
GTBP is trading near its 52-week low of $0.261 (13% above the low) on light trading volume (0.4× avg).
Summary
GT Biopharma reported a narrower Q2 loss but reiterated going concern doubts, unremediated material weakness, and Nasdaq delisting risk. The stock trades at $0.295, far below the $1.00 minimum bid requirement.
Key Events · Earnings and Guidance · GTBP
-
Q2 Loss Narrows
Net loss of $4.5M for Q2 2026, down from $30.2M in Q2 2025, driven by absence of prior year's $28.7M Greenshoe Rights liability charge.
-
Going Concern Warning
Company reiterates substantial doubt about its ability to continue as a going concern; cash of $5.1M will not fund operations through the next twelve months without additional financing.
-
Nasdaq Delisting Risk
Stock price of $0.295 is far below the $1.00 minimum bid requirement; company has until November 16, 2026 to regain compliance or face delisting.
-
Material Weakness Unremediated
Disclosure controls and procedures remain ineffective due to a material weakness in accounting for complex financial transactions, first identified in 2025.
Analysis · GTBP · Life Sciences
GT Biopharma's Q2 2026 net loss narrowed to $4.5M from $30.2M a year ago, but the company reiterated its going concern warning and disclosed that cash will not fund operations through the next twelve months without additional financing. The stock trades at $0.295, far below the $1.00 Nasdaq minimum, and the company has until November 16, 2026 to regain compliance or face delisting. A material weakness in internal controls remains unremediated, and the Series L Preferred conversion price has been reset to the $0.454 floor, triggering anti-dilution adjustments that have increased warrant share counts to 57.5M. These factors create significant downside risk for existing shareholders.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 37.9% of the 895 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.87%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GTBP was trading at $0.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.2M. The 52-week trading range was $0.26 to $1.74. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.